CRIS
Curis, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.35
−1.46%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.3M | 9.4M | 10.9M | 10.0M | 10.2M |
| Cost of Revenue | 31.0K | 45.0K | 98.0K | 212.0K | 257.0K |
| Gross Profit | 4.3M | 9.4M | 10.8M | 9.8M | 9.9M |
| Operating Expenses | |||||
| R&D Expense | 25.4M | 28.3M | 38.6M | 39.5M | 43.3M |
| SG&A Expense | 14.8M | 14.0M | 16.8M | 18.6M | 19.6M |
| General & Admin Expense | 14.8M | 14.0M | 16.8M | 18.6M | 19.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | 45.0K | — | — | — |
| Total Operating Expenses | 40.2M | 42.3M | 55.4M | 58.1M | 62.9M |
| Cost and Expenses | 40.3M | 42.3M | 55.5M | 58.4M | 63.2M |
| Operating Income (EBIT) | (36.0M) | (32.9M) | (44.5M) | (48.3M) | (53.0M) |
| Non-Operating | |||||
| Interest Income | 270.0K | 316.0K | 1.8M | 2.9M | 1.1M |
| Interest Expense | — | 2.2M | 615.0K | 2.0M | 4.8M |
| Net Interest Income | 270.0K | (1.9M) | 1.2M | 919.0K | (3.7M) |
| Other Non-Op Income/Expense | 14.8M | 25.3M | 1.2M | 919.0K | (3.7M) |
| Non-Operating Income (excl Interest) | (14.0M) | (27.5M) | (1.8M) | (2.9M) | (1.1M) |
| EBT (Pre-Tax Income) | (21.2M) | (7.6M) | (43.4M) | (47.4M) | (56.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (21.2M) | (7.6M) | (43.4M) | (47.4M) | (56.7M) |
| Earnings from Cont. Ops | (21.2M) | (7.6M) | (43.4M) | (47.4M) | (56.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (21.2M) | (7.6M) | (43.4M) | (47.4M) | (56.7M) |
| Per Share | |||||
| Basic EPS | ($14.22) | ($11.60) | ($137.60) | ($179.20) | ($242.80) |
| Diluted EPS | ($14.22) | ($11.60) | ($137.60) | ($179.20) | ($242.80) |
| Revenue Per Share | $2.02 | $14.35 | $34.59 | $37.87 | $43.52 |
| Shares | |||||
| Basic Shares Outstanding | 2.1M | 658201 | 315314 | 264664 | 233481 |
| Diluted Shares Outstanding | 2.1M | 658201 | 315314 | 264664 | 233481 |
| Profitability Metrics | |||||
| EBITDA | (21.8M) | (5.2M) | (42.6M) | (45.1M) | (51.7M) |
| D&A | 94.0K | 169.0K | 203.0K | 255.0K | 233.0K |
| EBIT | (21.9M) | (5.4M) | (42.8M) | (45.4M) | (51.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026